Want to see KROS full AI Analyst Report?

Keros Therapeutics (KROS) Price & Analysis

364 Followers

KROS Stock Chart & Stats

$11.67

-$0.58(-3.66%)

At close: Jan 08 4:00 PM EST

$11.67

-$0.58(-3.66%)

Day’s Range― - ―

52-Week Range$9.69 - $22.55

Previous CloseN/A

Volume109.28K

Average Volume (3M)279.77K

Market Cap

$238.10M

Enterprise Value$67.91M

Total Cash (Recent Filing)$281.50M

Total Debt (Recent Filing)$16.31M

Price to Earnings (P/E)―

Beta1.01

Next Earnings

Aug 12, 2026

EPS Estimate

-1.34

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.44

Shares Outstanding19,791,838

10 Day Avg. Volume373,782

30 Day Avg. Volume279,773

Financial Highlights & Ratios

PEG Ratio-0.06

Price to Book (P/B)2.50

Price to Sales (P/S)3.11

P/FCF Ratio7.15

Enterprise Value/Market Cap0.29

Enterprise Value/Revenue2.05

Enterprise Value/Gross Profit2.12

Enterprise Value/Ebitda-0.77

Forecast

1Y Price Target

$19.00

Price Target Upside62.81% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering7

EPS Forecast (FY)-6

Revenue Forecast (FY)$4.24M

Bulls Say, Bears Say

Bulls Say

Conservative Balance SheetVery low leverage (TTM debt ~$16.3M vs equity ~$285.6M; debt-to-equity ~0.03–0.06) provides financial flexibility to fund clinical programs and absorb development setbacks. This reduces near-term refinancing risk and supports program continuity over the next several months.

Focused TGF-β Therapeutic PipelineA concentrated scientific focus on modulating TGF-β pathways addresses high unmet needs in myelodysplastic syndromes, myelofibrosis, DMD and ALS. This specialization builds a durable technical moat and increases likelihood of strategic partnerships or licensing if clinical data progress.

Board And Governance StrengtheningAdding an experienced clinical-development executive to the board improves oversight of trial design, regulatory strategy and partner interactions. Stronger governance and investor-approved director slate supports disciplined execution and lowers program execution risk over the medium term.

Bears Say

Earnings And Revenue VolatilityA sharp swing from profitable 2025 to a loss-making TTM shows results are driven by irregular events (one-time milestones or nonrecurring items). Such volatility undermines revenue predictability and complicates multi-quarter planning for R&D and capital allocation.

Deteriorating Cash GenerationNegative operating and free cash flow in the TTM after prior-year inflows signals renewed cash burn. Persistent cash outflows increase the probability of near-term financing needs, which can raise dilution risk and constrain development timelines if additional capital or deals aren't secured.

Dependence On Irregular Revenue SourcesAs a clinical-stage biotech without product revenue, Keros relies on milestone-driven and partnership receipts plus capital markets. This structural reliance on nonrecurring income makes operating cash flows and funding availability unpredictable over the coming months.

Keros Therapeutics News

Keros Therapeutics’ TROPOS Trial Termination: What It Means for KROS Investors

Keros Therapeutics, Inc. ($KROS) announced an update on their ongoing clinical study. The TROPOS study, officially titled “A...

9d ago

KROS

Keros Therapeutics Appoints Anne Prener to Board

Keros Therapeutics ( ($KROS) ) has provided an update. On June 23, 2026, Keros Therapeutics’ board of directors...

16d ago

KROS

Keros Therapeutics Stockholders Approve Directors and Governance Matters

Keros Therapeutics ( ($KROS) ) has shared an announcement. On June 3, 2026, Keros Therapeutics stockholders held their...

1M ago

KROS

Keros Therapeutics CEO to Present at Goldman Sachs Conference

Keros Therapeutics ( ($KROS) ) has provided an announcement. On June 1, 2026, Keros Therapeutics, Inc. announced that...

1M ago

KROS

Hold Rating Reiterated on Keros as Takeda Partnership Progress Offsets Rinvatercept Delays; $16 Price Target Maintained

Analyst Yun Zhong from Wedbush maintained a Hold rating on Keros Therapeutics and keeping the price target at...

2M ago

KROS

Keros Therapeutics: Buy Rating Reaffirmed on Rinvatercept-Focused Strategy and Unchanged $20 Price Target

Analyst Andres Y. Maldonado of H.C. Wainwright reiterated a Buy rating on Keros Therapeutics, retaining the price target...

2M ago

KROS

Keros Therapeutics reports Q1 EPS ($1.21), consensus (92c)

Reports Q1 revenue $367,000, consensus $1.69M. “Continuing to progress our pipeline remains our top priority, setting the stage...

2M ago

KROS

Balanced Hold on Keros as Rinvatercept Progress Offsets Execution and Timeline Risks

TD Cowen analyst Nicholas Lorusso has maintained their neutral stance on KROS stock, giving a Hold rating yesterday....

4M ago

KROS

Keros Therapeutics Advances Rinvatercept in ALS Collaboration

Keros Therapeutics ( ($KROS) ) has shared an update. On March 9, 2026, Keros Therapeutics announced it has...

4M ago

KROS

Keros Therapeutics announces collaboration with Sean M. Healey & AMG Center

Keros Therapeutics (KROS) announced that it has entered into an agreement with the Massachusetts General Hospital, MGH, for...

4M ago

KROS

Keros Therapeutics presents additional data from Phase 1 of rinvatercept

Keros Therapeutics (KROS) announced that it presented additional data from its Phase 1 clinical trial of rinvatercept in...

4M ago

KROS

Keros Therapeutics’ Smaller Reporting Status Cuts Disclosure Burden but May Weigh on Investor Appeal and Volatility

Keros Therapeutics, Inc. (KROS) has disclosed a new risk, in the Share Price & Shareholder Rights category. Keros...

4M ago

KROS

Keros Therapeutics price target lowered to $20 from $23 at Wells Fargo

Wells Fargo lowered the firm’s price target on Keros Therapeutics (KROS) to $20 from $23 and keeps an...

4M ago

KROS

Keros Highlights Rinvatercept Strategy in Updated Investor Presentation

The latest update is out from Keros Therapeutics ( ($KROS) ). On March 4, 2026, Keros Therapeutics updated...

4M ago

KROS

KROS FAQ

What was Keros Therapeutics, Inc.’s price range in the past 12 months?

Keros Therapeutics, Inc. lowest stock price was $9.69 and its highest was $22.55 in the past 12 months.

What is Keros Therapeutics, Inc.’s market cap?

Keros Therapeutics, Inc.’s market cap is $238.10M.

When is Keros Therapeutics, Inc.’s upcoming earnings report date?

Keros Therapeutics, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 32 days.

How were Keros Therapeutics, Inc.’s earnings last quarter?

Keros Therapeutics, Inc. released its earnings results on May 14, 2026. The company reported -$1.21 earnings per share for the quarter, missing the consensus estimate of -$1.023 by -$0.187.

Is Keros Therapeutics, Inc. overvalued?

According to Wall Street analysts Keros Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Keros Therapeutics, Inc. pay dividends?

Keros Therapeutics, Inc. does not currently pay dividends.

What is Keros Therapeutics, Inc.’s EPS estimate?

Keros Therapeutics, Inc.’s EPS estimate is -1.34.

How many shares outstanding does Keros Therapeutics, Inc. have?

Keros Therapeutics, Inc. has 19,791,838 shares outstanding.

What happened to Keros Therapeutics, Inc.’s price movement after its last earnings report?

Keros Therapeutics, Inc. reported an EPS of -$1.21 in its last earnings report, missing expectations of -$1.023. Following the earnings report the stock price went down -8.34%.

Which hedge fund is a major shareholder of Keros Therapeutics, Inc.?

Currently, no hedge funds are holding shares in KROS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Keros Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-17.04%

Trailing 12-Months

Asset Growth

-60.20%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Keros Therapeutics, Inc.

Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.

Keros Therapeutics (KROS) Earnings & Revenues

Historic Earnings Reports

KROS Stock 12 Month Forecast

Average Price Target

$19.00

▲(62.81% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"$9","12":"$12","15":"$15","18":"$18","21":"$21"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$19.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,12,15,18,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.88,11.581538461538463,12.283076923076923,12.984615384615385,13.686153846153847,14.387692307692308,15.08923076923077,15.79076923076923,16.49230769230769,17.193846153846152,17.895384615384614,18.596923076923076,19.298461538461538,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.88,11.504615384615386,12.12923076923077,12.753846153846155,13.37846153846154,14.003076923076923,14.627692307692309,15.252307692307692,15.876923076923077,16.501538461538463,17.126153846153848,17.75076923076923,18.375384615384615,{"y":19,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.88,11.273846153846154,11.667692307692308,12.061538461538461,12.455384615384617,12.84923076923077,13.243076923076924,13.636923076923077,14.03076923076923,14.424615384615386,14.818461538461538,15.212307692307693,15.606153846153846,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.34,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.32,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.72,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.28,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.22,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.18,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.36,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.4,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.91,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.69,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.49,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.9,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.88,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >